Zobrazeno 1 - 10
of 262
pro vyhledávání: '"Peter A. O'Donnell"'
Autor:
Daniel Huang, Connor Lynch, Lucas M. Serra, Randy F. Sweis, Paul J. Chang, Walter M. Stadler, Russell Z. Szmulewitz, Peter H. O’Donnell, Abhinav Sidana, Scott E. Eggener, Arieh L. Shalhav, Stanley L. Liauw, Sean P. Pitroda
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 49, Iss , Pp 100879- (2024)
Background and purpose: Stereotactic ablative body radiotherapy (SABR) is an effective treatment for localized renal cell carcinoma (RCC). However, the role of primary site SABR for locally recurrent or metastatic RCC is unclear. Here, we report outc
Externí odkaz:
https://doaj.org/article/1a67d80417974116897b0aff6bb0ac82
Autor:
Jeffrey S. Damrauer, Wolfgang Beckabir, Jeff Klomp, Mi Zhou, Elizabeth R. Plimack, Matthew D. Galsky, Petros Grivas, Noah M. Hahn, Peter H. O’Donnell, Gopa Iyer, David I. Quinn, Benjamin G. Vincent, Diane Zipursky Quale, Sara E. Wobker, Katherine A. Hoadley, William Y. Kim, Matthew I. Milowsky
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
The Bladder Cancer Advocacy Network established the UC-GENOME study in order to create a biobank and data repository for metastatic urothelial carcinoma. Here, the authors present the first characterization and analysis of DNA and RNA sequencing data
Externí odkaz:
https://doaj.org/article/0bf19d5b29ef4d3b9204ad4bf88f3eed
Autor:
Loren Saulsberry, Keith Danahey, Brittany A. Borden, Elizabeth Lipschultz, Maimouna Traore, Mark J. Ratain, David O. Meltzer, Peter H. O’Donnell
Publikováno v:
npj Genomic Medicine, Vol 6, Iss 1, Pp 1-10 (2021)
Abstract Within an institutional pharmacogenomics implementation program, we surveyed 463 outpatients completing preemptive pharmacogenomic testing whose genetic results were available to providers for guiding medication treatment. We compared views
Externí odkaz:
https://doaj.org/article/3f295504c3594666b622a54863c65a46
Autor:
Tien M. Truong, Elizabeth Lipschultz, Keith Danahey, Emily Schierer, Mark J. Ratain, Peter H. O'Donnell
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 1, Pp 78-87 (2020)
Our objective was to build a mock pharmacogenomic (PGx) patient portal and assess its ability to disseminate test results and information to patients. The YourPGx Portal delivered four sample PGx results (omeprazole, simvastatin, clopidogrel, and cod
Externí odkaz:
https://doaj.org/article/84ac7d4875564282980ea5182cd1abf9
Autor:
Paula N. Friedman, Mohammed Shaazuddin, Li Gong, Robert L. Grossman, Arthur F. Harralson, Teri E. Klein, Norman H. Lee, Doriane C. Miller, Edith A. Nutescu, Travis J. O'Brien, Peter H. O'Donnell, Kevin J. O'Leary, Matthew Tuck, David O. Meltzer, Minoli A. Perera
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 3, Pp 209-217 (2019)
The majority of pharmacogenomic (PGx) studies have been conducted on European ancestry populations, thereby excluding minority populations and impeding the discovery and translation of African American–specific genetic variation into precision medi
Externí odkaz:
https://doaj.org/article/958635f1e72f454ab41a5ad58c2d1442
Autor:
Sharyn D. Baker, Susan E. Bates, Gabriel A. Brooks, William L. Dahut, Robert B. Diasio, Wafik S. El-Deiry, William E. Evans, William D. Figg, Dan L. Hertz, J. Kevin Hicks, Suneel Kamath, Pashtoon Murtaza Kasi, Todd C. Knepper, Howard L. McLeod, Peter H. O'Donnell, Mary V. Relling, Michelle A. Rudek, Tristan M. Sissung, D. Max Smith, Alex Sparreboom, Sandra M. Swain, Christine M. Walko
Publikováno v:
Journal of Clinical Oncology. 41:2701-2705
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bd1750e4c05931efd2a32d144bd9ec0
https://doi.org/10.1200/jco.22.02364
https://doi.org/10.1200/jco.22.02364
Autor:
Tien M. Truong, Jeffrey L. Apfelbaum, Keith Danahey, Emily Schierer, Jenna Ludwig, David George, Larry House, Theodore Karrison, Sajid Shahul, Magdalena Anitescu, Anish Choksi, Seth Hartman, Randall W. Knoebel, Xander M. R. van Wijk, Kiang-Teck J. Yeo, David O. Meltzer, Mark J. Ratain, Peter H. O’Donnell
Publikováno v:
Anesthesia and analgesia. 135(5)
Pharmacogenomics, which offers a potential means by which to inform prescribing and avoid adverse drug reactions, has gained increasing consideration in other medical settings but has not been broadly evaluated during perioperative care.The Implement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97e816d8f1de8d599d4d3de10ef3fa84
https://pubmed.ncbi.nlm.nih.gov/36269983
https://pubmed.ncbi.nlm.nih.gov/36269983
Autor:
Natalie Reizine, Everett E. Vokes, Ping Liu, Tien M. Truong, Rita Nanda, Gini F. Fleming, Daniel V.T. Catenacci, Alexander T. Pearson, Sandeep Parsad, Keith Danahey, Xander M. R. van Wijk, Kiang-Teck J. Yeo, Mark J. Ratain, Peter H. O’Donnell
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Many cancer patients who receive chemotherapy experience adverse drug effects. Pharmacogenomics (PGx) has promise to personalize chemotherapy drug dosing to maximize efficacy and safety. Fluoropyrimidines and irinotecan have well-known ge
Externí odkaz:
https://doaj.org/article/a4fbb785a980432cbc1cd3da35a7b36b
Autor:
Thomas Chen, Peter H. O’Donnell, Merisa Middlestadt, Gregory W. Ruhnke, Keith Danahey, Xander M.R. van Wijk, Anish Choksi, Randall Knoebel, Seth Hartman, Kiang-Teck Jerry Yeo, Paula N. Friedman, Mark J. Ratain, Edith A. Nutescu, Kevin J. O’Leary, Minoli A. Perera, David O. Meltzer
Publikováno v:
Pharmacogenetics and Genomics. 33:19-23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c4460655fb0b0d9b0abca278fe78e0a
https://doi.org/10.1097/fpc.0000000000000487
https://doi.org/10.1097/fpc.0000000000000487
Autor:
Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor, Prasanth Abraham, Jonathan E. Rosenberg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-16 (2017)
Abstract The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has dem
Externí odkaz:
https://doaj.org/article/a0d0c0551989418f9c28cf0b509924fb